Across its top 20 institutional holders, RCKT's holder base skews toward low-concentration, low-turnover investors on average (avg. concentration score 7/100, avg. turnover score 37/100).
Quarterly Activity
Recent Activity
+$152.7M
Total Buy Value
$156.4M
Total Sell Value
New buy41
Trim54
Add82
Sold out33
123
Net Buyers
87
Net Sellers
Smart Money Convergence
RCKT does not currently have enough recent insider (Form 4) trading activity to compute a convergence signal against its 13F institutional flows.
13F data as of 2026-06-30 quarterly filings. Note: many large institutions file close to the 45-day post-quarter deadline, so early-quarter flow figures can shift substantially as more filings arrive.
Insider Trading (Form 4)
Form 144 Pre-Sale Notices
1
Filings (90d)
$41K
Total Est. Value
11K shares
Planned Shares
Last Filed 2026-07-07
Filer
Title/Relationship
Filing Date
Planned Shares
Est. Value
Malik Fady Ibraham
Director
2026-07-07
11K shares
$41K
Form 144 is a planned sale notice, not an executed transaction. Form 144 Tracker。
Beneficial Ownership (13D/13G)
No Schedule 13D/13G filings for this ticker
Material Events (8-K)
1
Filings (14d)
Data as of 2026-06-30
2026-06-30
Rocket Pharmaceuticals announced the resignation of John Militello as VP of Finance, Senior Controller, Treasurer, and Principal Accounting Officer, effective July 7, 2026, to pursue other opportunities. On June 30, the company appointed Joseph Manhede, currently Associate Vice President, Corporate Controller, as the new Principal Accounting Officer, effective July 8, 2026. Manhede, 48, is a CPA with prior experience at Deloitte, Outlook Therapeutics, and other pharmaceutical companies. No new compensatory arrangements were made for this role.
Who are the top institutional investors holding ROCKET PHARMACEUTICALS INC (RCKT)?
Major stakeholders currently include Rtw Investments, LP ($63.3M), BlackRock, Inc. ($28.0M), Citigroup INC ($18.3M). Based on the latest 13F filings, there are a total of 198 tracked investment funds and institutions maintaining positions in RCKT.
What is the overall institutional sentiment toward RCKT recently?
Institutional sentiment appears Bullish (Net Buying). During the most recent reporting quarter, the stock experienced a net inflow of $26.1M, driven by 123 managers accumulating shares while 87 reduced their exposure.
Which institutions have been selling or reducing their RCKT positions?
In the latest period, 54 funds trimmed their holdings, and 33 managers completely exited their positions. The aggregate reported sell value was $156.4M.
Are there any notable investors adding RCKT to their portfolios?
Yes, buying activity remains notable. 41 institutions opened new positions in {ticker}, and 82 existing holders added to their shares. The total reported buy value for the quarter amounted to $152.7M.
Related Stocks
Trending Institutional Adds
The most-added stocks by 13F institutions this quarter